Fundz

NeoGenomics Appoints Tony Zook as Chief Executive Officer (CEO) to Succeed Chris Smith

PUBLIC · NEOJan 10, 2025

Company

NeoGenomics

Fort MyersBiotechnologyHealth CareMedicalHealth Diagnostics

Description

NeoGenomics, Inc. announced that Chris Smith will retire as Chief Executive Officer (CEO) and board member effective April 1, 2025. Tony Zook, an independent board member since 2023, will assume the role of CEO at that time

Quick answer

NeoGenomics Appoints Tony Zook as Chief Executive Officer (CEO) to Succeed Chris Smith (January 10, 2025). NeoGenomics is based in Fort Myers, Florida, United States.

What did NeoGenomics announce on January 10, 2025?
NeoGenomics, Inc. announced that Chris Smith will retire as Chief Executive Officer (CEO) and board member effective April 1, 2025.
What does NeoGenomics do?
Neogenomics is a leading cancer diagnostics company, providing comprehensive laboratory services.
Where is NeoGenomics based?
NeoGenomics is based in Fort Myers, Florida, United States.
Which similar companies made leadership changes around the same time?
AngioInsight (December 17, 2024), Pulse Biosciences, Inc. (January 10, 2025), United Mitochondrial Disease Foundation (January 10, 2025) and Oxford Cancer Analytics (January 9, 2025) also announced leadership changes within 45 days of NeoGenomics.

Source: Fundz verified event record.

Other recent leadership changes in Medical and Health Diagnostics

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Who to call at NeoGenomics, and when

A new leader at NeoGenomics brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day NeoGenomics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at NeoGenomics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at NeoGenomics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

NeoGenomics

Location

Fort Myers, Florida, United States

About

Neogenomics is a leading cancer diagnostics company, providing comprehensive laboratory services. They specialize in genetic testing and next-generation sequencing to enhance cancer treatment. The company aims to improve patient outcomes through innovative diagnostics. With consistent revenue growth, Neogenomics is expanding its influence in the clinical diagnostics market.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment NeoGenomics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Melody
Likely contact at this company
••••••••@••••••••

See Melody's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for NeoGenomics's next move

Learn about Strategic plan

NeoGenomics changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.